Complement Factor 3 Could Be an Independent Risk Factor for Mortality in Patients with HBV Related Acute-on-Chronic Liver Failure
Table 1
Clinical characteristics of the populations enrolled in the study.
Variables
NC ()
CHB ()
HBV-ACLF ()
Sex (male)
14
32
62
Age (years)
37.69 ± 2.93
37.69 ± 1.28
41.52 ± 1.47
ALT (U/L)
23.68 ± 2.30
529 (41–2424)
257 (25–1986)
AST (U/L)
23.56 ± 1.84
386 (55–2646)
225 (78–3023)
Tbil (mg/dL)
N.D.
9.50 (0.92–49.71)
28.82 (10.75–64.82)
PT (s)
N.D.
15.6 (12.5–21.2)
28.0 (20.2–60.6)
PTA (%)
N.D.
72 (46–113)
29 (11–40)
ALB (g/L)
N.D.
38.70 ± 0.69
33.88 ± 0.66
GLB (g/L)
N.D.
29.56 ± 0.87
31.58 ± 0.90
Na (mmol/L)
N.D.
139.0 (133.8–142.5)
137.2 (117.7–146.2)
Creatinine (mol/L)
N.D.
64.0 (42–117)
63.4 (37.5–267)
AFP (ng/mL)
N.D.
108.0 (1.7–1000)
53.5 (2.8–1112)
DNA (log10IU/mL)
N.D.
5.69 ± 0.24
5.58 ± 0.20
HBsAg-positive
0
35
65
HBsAb-positive
16
0
0
HBeAg-positive
0
18
28
HBeAb-positive
0
17
37
HBcAb-positive
0
35
65
Data are shown as means and standard error or median and range. ACLF, acute-on-chronic liver failure; CHB, chronic hepatitis B; NC, normal control; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; ALB, albumin; GLB, globulin; AFP, alpha-fetoprotein; and N.D., not determined. HBV-DNA could not be detected in 10 patients with HBV-ACLF.
